// App-Quantinova.ai

[FRI0318] : TWO-YEAR RETENTION AND EFFECTIVENESS OF IV ABATACEPT IN REAL-LIFE SETTING: RESULTS FROM THE ACTION STUDY

Researchers

Presenter

  • H. Nusslein

Principal Investigators

  • R. Alten

  • M. Galeazzi

  • C. Rauch

  • M. Le Bars

  • H. M. Lorenz

  • M. Nurmohamed

  • W. Bensen

  • G. R. Burmester

  • H. H. Peter

  • K. Pavelka

  • M. Chartier

  • C. Poncet

Medical Centers

  • St Joseph's Hospital/McMaster University, Ontario, Canada

  • Charles Univ and VFN, Prague, Czech Republic

  • Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

  • Docs International, Nanterre, France

  • Heidelberg University Hospital, Heidelberg, Germany

  • University Hospital of Siena, Siena, Italy

  • Schlosspark-Klinik University Medicine, Berlin, Germany

  • University Medical Center Freiburg, Freiburg, Germany

Locations

  • Canada

  • Czech Republic

  • Italy

  • Netherlands

  • Germany

  • France

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Deep vein thrombosis

  • Rheumatoid arthritis

  • Cytomegalovirus infection

  • Venous thrombosis

  • Inflammatory Arthritis

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

  • Abatacept

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved